Table 1 Patient Demographics, Pregnancy Characteristics, and Leptin Levels
Variable | Successful IOL (vaginal delivery) N = 115 | Failed IOL (Cesarean section delivery) N = 59 | P Value |
|---|---|---|---|
Maternal Age at Delivery (mean years, 95% CI) | 29.6 (28.6–30.6) | 29.9 (28.6–31.2) | 0.7 |
Race: White | 87.8% (101) | 93.2% (55) | 0.7 |
Race: Black | 2.6% (3) | 1.7% (1) | 0.7 |
Race: Asian | 3.5% (4) | 1.7% (1) | 0.7 |
Race: Hispanic | 1.7% (2) | 0% (0) | 0.7 |
Race: American Indian | 0% (0) | 1.7% (1) | 0.7 |
Race: Unspecified | 3% (3) | 1.7% (1) | 0.7 |
Race: Multiracial | 1.7% (2) | 0% (0) | Â |
BMI (mean kg/m2, 95% CI) | 27.4 (26.2–28.6) | 32.2 (29.9–40.0) | 0.0002 |
GA at IOL (mean weeks, 95% CI) | 39.8 (39.6–40.0) | 39.5 (39.2–39.8) | 0.2 |
Bishop Score (mean, 95% CI) | 4.6 (4.1–5.1) | 2.6 (2.1–3.1) | < 0.001 |
Parity (mean, 95% CI) | 0.9 (0.7–1.1) | 0.3 (0.1–0.5) | < 0.001 |
Epidural/Spinal (%, N) | 84.3% (97) | 83.1% (49) | 0.9 |
Weight Gain (mean kg, 95% CI) | 12.7 (11.5–13.9) | 13.0 (11.4–14.6) | 0.8 |
Induction Method | |||
 Cervidil (dinoprostone) (%, N) | 28.6% (33) | 64.4% (38) | < 0.001 |
 Cytotec (misoprostol) (%, N) | 30.4% (35) | 44.1% (26) | 0.1 |
 Pitocin (%, N) | 86.1% (99) | 91.5% (54) | 0.5 |
 Foley Bulb (%, N) | 11.3% (13) | 27.1% (16) | 0.03 |
 AROM (%, N) | 55.6% (64) | 50.8% (30) | 0.7 |
 Nipple Stimulation (%, N) | 0.87% (1) | 0% | 0.7 |
 Multiple IOL Methods (%, N) | 73.9% (85) | 93.2% (55) | 0.008 |
Indication for IOL | |||
 IOL PET (%, N) | 1.7% (2) | 13.5% (8) | 0.008 |
 IOL AMA (%, N) | 11.3% (13) | 18.6% (11) | 0.2 |
 IOL Fetal Indication (%, N) | 18.2% (21) | 13.5% (8) | 0.5 |
 IOL GDM (%, N) | 7.8% (9) | 3.4% (2) | 0.5 |
 IOL DM I (%, N) | 0.87% (1) | 6.8% (4) | 0.2 |
 IOL DM II (%, N) | 0% (0) | 1.7% (1) | 0.7 |
 IOL CHTN (%, N) | 11.3% (13) | 15.2% (9) | 0.6 |
 IOL gHTN (%, N) | 8.6% (10) | 3.4% (2) | 0.4 |
 IOL Postdates (%, N) | 28.6% (33) | 30.5% (18) | 0.9 |
 IOL PROM (%, N) | 6.1% (7) | 6.8% (4) | 0.8 |
 IOL Elective (%, N) | 25.2% (29) | 8.5% (5) | 0.03 |
 IOL Multiple Indications (%, N) | 19.1% (22) | 18.6% (11) | 0.9 |
Antepartum/Intrapartum Complications | |||
 No Pregnancy Complications (%, N) | 45.2% (52) | 30.5% (18) | 0.06 |
 CHTN (%, N) | 11.3% (13) | 15.2% (9) | 0.06 |
 gHTN (%, N) | 8.6% (10) | 3.4% (2) | 0.4 |
 Preeclampsia (%, N) | 1.7% (2) | 13.5% (8) | 0.008 |
 DM I (%, N) | 0.8% (1) | 6.7% (4) | 0.07 |
 DM II (%, N) | 0% (0) | 1.7% (1) | 0.2 |
 GDM A1 (%, N) | 4.3% (5) | 3.4% (2) | 0.7 |
 GDM A2 (%, N) | 6.1% (7) | 3.4% (2) | 0.7 |
 Alloimmunization (%, N) | 0.8% (1) | 1.7% (1) | 0.8 |
 IUGR (%, N) | 1.7% (2) | 0% (0) | 0.8 |
 Oligohydramnios (%, N) | 7.8% (9) | 1.7% (1) | 0.2 |
 Cerclage (%, N) | 2.6% (3) | 1.7% (1) | 0.8 |
 Hypothyroid (%, N) | 11.3% (13) | 8.5% (5) | 0.9 |
 AMA (%, N) | 12.2% (14) | 18.6% (11) | 0.4 |
 History of Cesarean Section (%, N) | 4.3% (5) | 1.7% (1) | 0.7 |
 VBAC (%, N) | 1.7% (2) | 0% (0) | 0.8 |
 Operative Vaginal Delivery (%, N) | 14.8% (17) | 0% (0) | 0.007 |
 Meconium (%, N) | 13.0% (15) | 35.6% (21) | 0.002 |
 Chorioamnionitis (%, N) | 7.8% (9) | 13.6% (8) | 0.4 |
 Gestational age at sample collection | 39 5/7 weeks | 38 5/7 weeks | 0.26 |
 Leptin (pg/ug) | 0.3 (0.3–0.4) | 0.5 (0.4–0.7) | 0.01 |